What is lymphomatoid papulosis?
Lymphomatoid papulosis (LyP) is a long-term skin condition in which small red or red-brown bumps appear in crops, break down in the centre and then heal by themselves within a few weeks. New bumps keep appearing, often for many years.
The bumps contain abnormal T lymphocytes, a type of white blood cell, that carry a marker called CD30. Because of this, LyP is classed with primary cutaneous anaplastic large cell lymphoma as a primary cutaneous CD30-positive T-cell lymphoproliferative disorder (Willemze et al., 2019).
Under the microscope, LyP can look like an aggressive lymphoma. In reality it behaves in a benign way, and the skin lesions themselves never spread to internal organs. The name “lymphomatoid” means “lymphoma-like”.
LyP has an excellent outlook, with a survival close to that of the general population. However, people with LyP have a higher chance of developing another lymphoma, most often mycosis fungoides, cutaneous anaplastic large cell lymphoma or Hodgkin lymphoma.
For this reason, people with LyP need regular, long-term check-ups with a dermatologist or haematologist.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Primary cutaneous CD30-positive T-cell lymphoproliferative disorder |
| How common | Rare; about 1-2 new cases per million people each year |
| Typical age | Any age, median about 45; also children |
| Sex | Slightly more common in men |
| Main sign | Crops of self-healing red-brown bumps |
| Where on the body | Mainly the trunk, arms and legs |
| Associated lymphoma | Develops in a minority over time; lifelong follow-up needed |
| Main treatments | Observation, topical steroids, low-dose methotrexate, phototherapy |
| Outlook | Excellent; 5-year survival close to 100% |
2. Causes and risk factors
The cause of LyP is not known. It is not infectious, is not inherited and cannot be passed on to others.
| Factor | What is known |
|---|---|
| Immune system | The immune system seems to keep the abnormal T cells in check, explaining why lesions heal by themselves |
| Clonal T cells | The T cells in many lesions are a clone, meaning they come from one parent cell |
| Atopy and bacteria | Research suggests eczema-like skin inflammation and staphylococcal toxins may play a part in some people (Kadin et al., 2020) |
| Gene changes | A small subset carries a rearrangement of the DUSP22-IRF4 region on chromosome 6 |
3. Types of lymphomatoid papulosis
Pathologists recognise several types based on how the cells look under the microscope. These types all look and behave similarly on the skin, and they do not differ in outlook.
Knowing the type matters mainly because each can be mistaken for a different, more aggressive lymphoma (Kempf et al., 2011).
| Type | Microscope features | Could be mistaken for |
|---|---|---|
| Type A | Scattered large CD30-positive cells in a wedge-shaped mixed inflammatory infiltrate; most common (about three-quarters) | Hodgkin lymphoma |
| Type B | Small cells with folded nuclei in the upper skin; CD30 may be weaker | Mycosis fungoides |
| Type C | Sheets of large CD30-positive cells | Anaplastic large cell lymphoma |
| Type D | CD8-positive cells spreading into the upper skin | Aggressive CD8-positive cutaneous lymphoma |
| Type E | Cells invading blood vessel walls, causing large ulcers | Angiocentric lymphomas |
| DUSP22-rearranged | Two-layer pattern of small and medium cells | Mycosis fungoides or ALCL |
4. How does it look
LyP has a very typical appearance and life cycle. Recognising the pattern is often the key to diagnosis.
Life cycle of a lesion
| Stage | What it looks like | Timing |
|---|---|---|
| New papule | A small, firm, red or red-brown bump, usually under 1 cm | Appears over a few days |
| Mature lesion | Grows slightly; may develop a small blister or pustule on top | 1-2 weeks |
| Breakdown | The centre turns dark, crusted or bleeds; a black scab may form | 2-4 weeks |
| Healing | The scab falls off and the bump flattens | 3-8 weeks overall |
| After healing | A brown or pale mark, or a small pitted scar like a chickenpox scar | Can last months |
Overall pattern
- Bumps appear in crops, so lesions at different stages are seen at the same time
- The number varies from a few to hundreds
- They most often appear on the trunk, buttocks, arms and legs; the face, palms, soles and mouth are less often affected
- Most lesions are smaller than 1-2 cm
- Type E lesions may become larger ulcers with a thick black crust before healing
A single lesion larger than 2 cm that does not heal within about 12 weeks should be biopsied. It may be cutaneous anaplastic large cell lymphoma rather than LyP.
5. Symptoms
Many people with LyP feel completely well in themselves. The main problems are the appearance of the skin lesions and, sometimes, discomfort.
Common symptoms
- Crops of red-brown bumps that come and go
- Itching, which can be mild or troublesome
- Tenderness or soreness, particularly when lesions break down
- Scabbing and bleeding from the centre of lesions
- Marks and small scars where lesions have healed
- Self-consciousness or distress about the appearance of the skin
Symptoms that need prompt review
Some symptoms may indicate an associated lymphoma and should be checked promptly:
| Symptom | Possible meaning |
|---|---|
| Persistent red, scaly patches or plaques | Mycosis fungoides |
| A lump that keeps growing and does not heal | Cutaneous anaplastic large cell lymphoma |
| Swollen lymph glands | Lymph node involvement or Hodgkin lymphoma |
| Fevers, night sweats, weight loss | Systemic lymphoma |
| Persistent itching all over | Possible associated lymphoma |
When to see a doctor
See a doctor or dermatologist if you notice recurring bumps that crust and heal by themselves, especially if they keep coming back over weeks or months.
If you already have LyP, report any lesion that does not heal, new patches or swollen glands.
6. Diagnosis
LyP is diagnosed by combining the typical history of self-healing lesions with a skin biopsy. The biopsy alone can be misleading, because some types look very like aggressive lymphoma.
| Test | Purpose |
|---|---|
| Clinical history and photographs | Documents the self-healing pattern |
| Skin biopsy | Shows the type of infiltrate and CD30-positive cells; ideally from a fresh, fully formed lesion |
| Immunohistochemistry | CD30, CD4, CD8 and other markers |
| T-cell receptor gene studies | Show whether the T cells are a clone |
| Full skin examination | Looks for signs of mycosis fungoides or other lymphoma |
| Blood tests | Full blood count, LDH and other routine tests |
| Lymph node examination | Checks for enlarged glands |
| Scans | Not routinely needed; used if an associated lymphoma is suspected |
Conditions that can look similar
| Condition | Key difference |
|---|---|
| Pityriasis lichenoides (PLEVA) | Also has self-healing crusted bumps but lacks CD30-positive large cells |
| Insect bites or scabies | Usually linked to exposure and itching; biopsy differs |
| Folliculitis | Centred on hair follicles |
| Cutaneous anaplastic large cell lymphoma | Larger tumours that persist |
| Viral infections | May contain CD30-positive cells but resolve completely |
How LyP compares with related skin conditions
| Feature | Lymphomatoid papulosis | Cutaneous ALCL | Mycosis fungoides |
|---|---|---|---|
| Typical lesions | Small bumps that heal by themselves | One or a few larger nodules or tumours | Flat scaly patches and thicker plaques |
| Course | Comes and goes in crops | Persistent, though some regress | Slowly progressive over years |
| CD30-positive cells | Yes | Yes, in sheets | Usually few, except in transformation |
| Usual treatment | Observation, methotrexate, phototherapy | Surgery or radiotherapy | Skin-directed treatments |
| Outlook | Excellent | Excellent for skin-only disease | Very good in early stages |
These conditions belong to the same family and can occur in the same person, which is why careful long-term follow-up matters.
7. Treatment
There is no treatment that cures LyP or permanently stops new lesions. Treatment also does not appear to prevent the development of an associated lymphoma.
The aim is therefore to control lesions when they are troublesome, while avoiding treatments with more side effects than the disease itself. International consensus recommendations guide care (Kempf et al., 2011).
| Treatment | When it is used | Notes |
|---|---|---|
| Watchful waiting | Few lesions, little discomfort | Many people choose no treatment |
| Strong topical steroids | Small numbers of lesions | Can speed healing |
| Low-dose methotrexate (weekly tablets or injection) | Many lesions, scarring or distress | The most effective standard treatment; lesions often return when stopped (Vonderheid et al., 1996) |
| Phototherapy (PUVA or narrowband UVB) | Widespread lesions | Effective; lesions may return after the course |
| Bexarotene or interferon | Second-line options | Used in some centres |
| Brentuximab vedotin | Severe disease not responding to other treatments | An antibody against CD30; highly effective but can cause nerve damage (Duvic et al., 2015; Lewis et al., 2017) |
| Surgery or radiotherapy | Single large or persistent lesions | Occasionally used |
Chemotherapy combinations used for lymphoma are not appropriate for LyP. Lesions come back quickly afterwards, and the side effects are significant.
8. Outlook (prognosis)
The outlook for LyP is excellent. Large studies show that disease-specific survival is close to 100% (Bekkenk et al., 2000).
LyP usually lasts for years or decades. In some people it eventually settles, while in others it continues throughout life.
Risk of an associated lymphoma
| Feature | Details |
|---|---|
| How often | Reported in about 10-20% in many series, and higher in some specialist centre studies (Wieser et al., 2016) |
| Most common types | Mycosis fungoides, cutaneous ALCL and Hodgkin lymphoma |
| Timing | Can occur before, at the same time as or many years after LyP |
| Effect on outlook | Depends on the type; most associated cutaneous lymphomas are slow-growing |
9. Lymphomatoid papulosis in children
LyP also occurs in children and teenagers. A systematic review found that the appearance and course are similar to those in adults (Wieser et al., 2016).
In children, LyP is often first mistaken for insect bites, chickenpox or pityriasis lichenoides. Most children are managed with watchful waiting, topical steroids or phototherapy, and some outgrow the condition.
Long-term follow-up into adulthood is still recommended.
10. Living with lymphomatoid papulosis
| Concern | What helps |
|---|---|
| Itching | Moisturisers, antihistamines and topical steroids |
| Scarring and marks | Early treatment of troublesome crops; avoid picking scabs |
| Appearance | Clothing choices, camouflage make-up and psychological support if distressing |
| Sun exposure | Moderate sunlight may help some people, but sunburn should be avoided |
| Worry about lymphoma | Regular follow-up and clear advice on warning signs |
Follow-up
Most people are seen every 6-12 months, and more often when the disease is active or treatment is being adjusted.
Follow-up includes a full skin check, an examination of the lymph glands and blood tests as needed. Taking photographs of lesions between appointments can be very helpful.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is LyP a cancer? | It is classed among the cutaneous T-cell lymphoproliferative disorders but behaves in a benign way |
| Is it contagious? | No. It cannot be passed to other people |
| Will it go away? | It may settle after years, but it often continues on and off for a long time |
| Do I need chemotherapy? | No. Strong chemotherapy is not recommended for LyP |
| Why do I need lifelong check-ups? | Because of the increased risk of developing another lymphoma |
12. Questions to ask your doctor
- Which type of LyP do I have?
- Do I need treatment, or is watching and waiting reasonable?
- What are the benefits and side effects of methotrexate or phototherapy?
- Which signs should make me contact you sooner?
- How often will I be followed up, and by whom?
- Is there any sign of an associated lymphoma?
Resources
- Kempf, W. et al. (2011) ‘EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma’, Blood, 118(15), pp. 4024-4035.
- Willemze, R. et al. (2019) ‘The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas’, Blood, 133(16), pp. 1703-1714.
- Bekkenk, M.W. et al. (2000) ‘Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment’, Blood, 95(12), pp. 3653-3661.
- Wieser, I. et al. (2016) ‘Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients’, Journal of the American Academy of Dermatology, 74(1), pp. 59-67.
- Wieser, I. et al. (2016) ‘Lymphomatoid papulosis in children and adolescents: a systematic review’, American Journal of Clinical Dermatology, 17(4), pp. 319-327.
- Martinez-Cabriales, S.A. et al. (2020) ‘Lymphomatoid papulosis: an update and review’, Journal of the European Academy of Dermatology and Venereology, 34(1), pp. 59-73.
- Vonderheid, E.C. et al. (1996) ‘Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders’, Journal of the American Academy of Dermatology, 34(3), pp. 470-481.
- Duvic, M. et al. (2015) ‘Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis’, Journal of Clinical Oncology, 33(32), pp. 3759-3765.
- Lewis, D.J. et al. (2017) ‘Brentuximab vedotin for patients with refractory lymphomatoid papulosis: an analysis of phase 2 results’, JAMA Dermatology, 153(12), pp. 1302-1306.
- Kadin, M.E. et al. (2020) ‘Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder’, PLoS One, 15(2), e0228751.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
Prepared by the editorial team, October 2026.